美国皮肤科药物市场：市场规模、份额、趋势分析（按治疗方法、类型、给药途径、药物类别、分销管道和地区）、细分市场预测（2025-2030 年）

美国皮肤病药物市场的成长与趋势：

根据 Grand View Research, Inc. 的一份新报告，美国皮肤病治疗市场预计到 2030 年将达到 144.8 亿美元，2025 年至 2030 年期间的复合年增长率为 9.7%。

这一市场的成长得益于针对慢性皮肤病的新型治疗方法的出现，以及痤疮、干癣等皮肤问题的日益普遍。此外，人们越来越意识到皮肤健康在整体健康中的重要性，这也促进了市场的成长。

此外，对研发的大量投资促进了新药的开发，这些新药可在柜檯购买，使治疗更加容易获得，从而促进了整体成长。最近，几家製药和消费者保健公司已获得美国FDA核准，批准其生产基于治疗严重皮肤病和改善患者预后的创新产品。

新型药物输送系统的出现以及市场参与企业对皮肤病学领域合作研究的日益关注也在市场成长中发挥关键作用。预计在预测期内，大量个人寻求可负担的治疗、零售药局提供的非处方药、以及提供快速送货和网上销售等新服务的零售商不断扩大的产品范围将为该市场提供有利的成长机会。

美国皮肤科药物市场：概览

• 到 2024 年，干癣将在治疗领域占据主导地位，份额超过 35.0%。这是因为大量患者寻求有效的干癣治疗，而市场参与企业正专注于提供新颖的治疗方法。
• 在美国，预计预测期内皮肤科痤疮药物将以显着的复合年增长率成长。
• 到 2024 年，处方笺皮肤病药物将占据最大的市场占有率，达到 77.5%。预计预测期内场外交易（OTC）部分将显着成长。
• 局部用药以其更好的患者体验、患者友善的给药系统和易于使用等优势，在 2024 年占据了美国皮肤病药物市场的主导地位，收入份额为 60.0%。预计在预测期内，肠外药物部门的复合年增长率最快，为 10.7%。
• 研发投入的不断增加、许多新药和新产品的核准以及零售药局的便利性都促进了美国皮肤病药物市场的成长。

目录

第一章 分析方法及范围

第 2 章执行摘要

第 3 章美国皮肤病药物市场：驱动因素、趋势与范围

• 市场联动展望
• 市场动态
  • 市场驱动因素分析
  • 市场限制分析
• 商业环境分析
  • 产业分析：波特五力分析
  • PESTEL 分析

第 4 章。美国皮肤病药物市场：按治疗方法类型的估计和趋势分析

• 治疗方法的市场占有率（2024 年和 2030 年）
• 治疗方法仪表板
• 市场规模预测及治疗方法趋势分析（2018-2030）
• 粉刺
  • 痤疮市场（2018-2030）
• 干癣
  • 干癣市场（2018-2030）
• 酒糟
  • 酒糟市场（2018-2030）
• 脱髮症
  • 脱髮症市场（2018-2030）
• 其他的
  • 其他市场（2018-2030）

第 5 章：美国皮肤病药物市场：按类型分類的估计和趋势分析

• 按类型分類的市场占有率（2024 年和 2030 年）
• 按类型分類的仪表板
• 按类型分類的市场规模预测及趋势分析（2018-2030）
• 处方笺
  • 处方药市场（2018-2030）
• 场外交易（OTC）
  • 非处方药 (OTC) 市场（2018-2030 年）

第六章美国皮肤病药物市场：按给药途径的估计和趋势分析

• 按管理途径分類的市场占有率（2024 年和 2030 年）
• 管理路线仪表板
• 依管理途径分類的市场规模预测及趋势分析（2018-2030 年）
• 局部给药
  • 局部递送市场（2018-2030）
• 口服
  • 口服给药市场（2018-2030）
• 肠外给药
  • 肠外给药市场（2018-2030）

第 7 章。美国皮肤科药物市场：按药物类别的估计和趋势分析

• 按药物类别分類的市场占有率（2024 年和 2030 年）
• 药品类别仪表板
• 依药物类别分類的市场规模预测及趋势分析（2018-2030年）
• 皮质类固醇
  • 皮质类固醇市场（2018-2030）
• 类视色素
  • 类视色素市场（2018-2030）
• 抗生素
  • 抗生素市场（2018-2030）
• 抗真菌药物
  • 抗真菌药物市场（2018-2030）
• Calcineurin抑制剂
  • Calcineurin抑制剂市场（2018-2030）
• 其他的
  • 其他市场（2018-2030）

第 8 章：美国皮肤病药物市场：按分销管道进行的估计和趋势分析

• 按分销管道分類的市场占有率（2024 年和 2030 年）
• 分销通路仪表板
• 按分销管道分類的市场规模预测及趋势分析（2018-2030 年）
• 医院药房
  • 医院药局市场（2018-2030）
• 零售药局
  • 零售药局市场（2018-2030）
• 其他的
  • 其他市场（2018-2030）

第九章 竞争格局

• 参与企业概况
• 公司市场地位分析
• 公司分类
• 战略地图
• 公司简介/上市公司
  • AbbVie Inc.
  • Pfizer Inc.
  • GSK plc.
  • LEO Pharma A/S
  • Sun Pharmaceutical Industries Ltd.
  • GALDERMA
  • Amgen Inc.
  • Johnson &Johnson Services Inc.
  • Novartis AG
  • Eli Lilly and Company
  • Almirall, SA
  • Bausch Health Companies Inc.

U.S. Dermatological Drugs Market Growth & Trends:

The U.S. dermatological drugs market size is anticipated to reach USD 14.48 billion by 2030, expanding at a CAGR of 9.7% from 2025 to 2030, according to a new report by Grand View Research, Inc. The growth of the market is driven by the availability of novel treatments designed for chronic skin diseases and the increasing prevalence of skin problems such as acne, psoriasis, and others. Increasing awareness regarding the significance of skin health in overall well-being also contributes to the growth.

Moreover, significant investments in research and development lead to new medications, and the availability of over-the-counter products makes treatments more accessible, contributing to overall growth. In recent years, multiple pharmaceutical and consumer healthcare companies have received U.S. FDA approvals for innovation-based products developed to treat severe skin conditions and enhance patient outcomes.

The emergence of new drug delivery systems and key market participants turning to collaboration-based research efforts in dermatology have also played vital roles in the market's growth. The large number of individuals seeking affordable treatments, the availability of over-the-counter products across retail pharmacies, and retailer service expansions with novel offerings such as fast delivery and online distribution are projected to add lucrative growth opportunities for this market over the forecast period.

U.S. Dermatological Drugs Market Report Highlights:

• Psoriasis dominated the therapy segment with more than 35.0% share in 2024, owing to many individuals seeking effective treatment for psoriasis and the focus of market participants on the delivery of novel therapies
• Dermatological drugs for acne are expected to grow at a significant CAGR in the U.S. over the forecast period
• The prescription-based dermatological drugs held the largest market share, 77.5%, in 2024. The over-the-counter segment is anticipated to witness significant growth over the forecast period
• Topical administration dominated the U.S. dermatological drugs market, with a revenue share of 60.0% in 2024, owing to patients' treatment experiences, patient-friendly delivery systems, and ease of use. The parenteral administration segment is expected to witness the fastest CAGR of 10.7% over the forecast period
• Increasing investments in research and development, approvals received for numerous novel therapies and products, and convenience offered by retail pharmacies are contributing to the growth of the U.S. dermatological drugs market.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Therapy
  • 1.2.2. Type
  • 1.2.3. Route of Administration
  • 1.2.4. Drug Class
  • 1.2.5. Distribution Channel
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
• 1.6. Information Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Data Visualization
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
• 1.9. List of Secondary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. U.S. Dermatological Drugs Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Business Environment Analysis
  • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
    • 3.3.1.1. Supplier Power
    • 3.3.1.2. Buyer Power
    • 3.3.1.3. Substitution Threat
    • 3.3.1.4. Threat of New Entrants
    • 3.3.1.5. Competitive Rivalry
  • 3.3.2. PESTLE Analysis

Chapter 4. U.S. Dermatological Drugs Market: Therapy Estimates & Trend Analysis

• 4.1. Therapy Market Share, 2024 & 2030
• 4.2. Therapy Segment Dashboard
• 4.3. Market Size & Forecasts and Trend Analysis, by Therapy, 2018 to 2030 (USD Million)
• 4.4. Acne
  • 4.4.1. Acne Market, 2018 - 2030 (USD Million)
• 4.5. Psoriasis
  • 4.5.1. Psoriasis Market, 2018 - 2030 (USD Million)
• 4.6. Rosacea
  • 4.6.1. Rosacea Market, 2018 - 2030 (USD Million)
• 4.7. Alopecia
  • 4.7.1. Alopecia Market, 2018 - 2030 (USD Million)
• 4.8. Others
  • 4.8.1. Others Market, 2018 - 2030 (USD Million)

Chapter 5. U.S. Dermatological Drugs Market: Type Estimates & Trend Analysis

• 5.1. Type Market Share, 2024 & 2030
• 5.2. Type Segment Dashboard
• 5.3. Market Size & Forecasts and Trend Analysis, by Type, 2018 to 2030 (USD Million)
• 5.4. Prescription
  • 5.4.1. Prescription Market, 2018 - 2030 (USD Million)
• 5.5. Over-the-Counter (OTC)
  • 5.5.1. Over-the-Counter (OTC) Market, 2018 - 2030 (USD Million)

Chapter 6. U.S. Dermatological Drugs Market: Route of Administration Estimates & Trend Analysis

• 6.1. Route of Administration Market Share, 2024 & 2030
• 6.2. Route of Administration Segment Dashboard
• 6.3. Market Size & Forecasts and Trend Analysis, by Route of Administration, 2018 to 2030 (USD Million)
• 6.4. Topical Administration
  • 6.4.1. Topical Administration Market, 2018 - 2030 (USD Million)
• 6.5. Oral Administration
  • 6.5.1. Oral Administration Market, 2018 - 2030 (USD Million)
• 6.6. Parenteral Administration
  • 6.6.1. Parenteral Administration Market, 2018 - 2030 (USD Million)

Chapter 7. U.S. Dermatological Drugs Market: Drug Class Estimates & Trend Analysis

• 7.1. Drug Class Channel Market Share, 2024 & 2030
• 7.2. Drug Class Channel Segment Dashboard
• 7.3. Market Size & Forecasts and Trend Analysis, by Drug Class, 2018 to 2030 (USD Million)
• 7.4. Corticosteroids
  • 7.4.1. Corticosteroids Market, 2018 - 2030 (USD Million)
• 7.5. Retinoids
  • 7.5.1. Retinoids Market, 2018 - 2030 (USD Million)
• 7.6. Antibiotics
  • 7.6.1. Antibiotics Market, 2018 - 2030 (USD Million)
• 7.7. Antifungals
  • 7.7.1. Antifungals Market, 2018 - 2030 (USD Million)
• 7.8. Calcineurin Inhibitors
  • 7.8.1. Calcineurin Inhibitors Market, 2018 - 2030 (USD Million)
• 7.9. Others
  • 7.9.1. Others Market, 2018 - 2030 (USD Million)

Chapter 8. U.S. Dermatological Drugs Market: Distribution Channel Estimates & Trend Analysis

• 8.1. Distribution Channel Market Share, 2024 & 2030
• 8.2. Distribution Channel Segment Dashboard
• 8.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2018 to 2030 (USD Million)
• 8.4. Hospital Pharmacies
  • 8.4.1. Hospital Facilities Market, 2018 - 2030 (USD Million)
• 8.5. Retail Pharmacies
  • 8.5.1. Retail Facilities Market, 2018 - 2030 (USD Million)
• 8.6. Ohers
  • 8.6.1. Others Market, 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Participant Overview
• 9.2. Company Market Position Analysis
• 9.3. Company Categorization
• 9.4. Strategy Mapping
• 9.5. Company Profiles/Listing
  • 9.5.1. AbbVie Inc.
    • 9.5.1.1. Overview
    • 9.5.1.2. Financial Performance
    • 9.5.1.3. Product Benchmarking
    • 9.5.1.4. Strategic Initiatives
  • 9.5.2. Pfizer Inc.
    • 9.5.2.1. Overview
    • 9.5.2.2. Financial Performance
    • 9.5.2.3. Product Benchmarking
    • 9.5.2.4. Strategic Initiatives
  • 9.5.3. GSK plc.
    • 9.5.3.1. Overview
    • 9.5.3.2. Financial Performance
    • 9.5.3.3. Product Benchmarking
    • 9.5.3.4. Strategic Initiatives
  • 9.5.4. LEO Pharma A/S
    • 9.5.4.1. Overview
    • 9.5.4.2. Financial Performance
    • 9.5.4.3. Product Benchmarking
    • 9.5.4.4. Strategic Initiatives
  • 9.5.5. Sun Pharmaceutical Industries Ltd.
    • 9.5.5.1. Overview
    • 9.5.5.2. Financial Performance
    • 9.5.5.3. Product Benchmarking
    • 9.5.5.4. Strategic Initiatives
  • 9.5.6. GALDERMA
    • 9.5.6.1. Overview
    • 9.5.6.2. Financial Performance
    • 9.5.6.3. Product Benchmarking
    • 9.5.6.4. Strategic Initiatives
  • 9.5.7. Amgen Inc.
    • 9.5.7.1. Overview
    • 9.5.7.2. Financial Performance
    • 9.5.7.3. Product Benchmarking
    • 9.5.7.4. Strategic Initiatives
  • 9.5.8. Johnson & Johnson Services Inc.
    • 9.5.8.1. Overview
    • 9.5.8.2. Financial Performance
    • 9.5.8.3. Product Benchmarking
    • 9.5.8.4. Strategic Initiatives
  • 9.5.9. Novartis AG
    • 9.5.9.1. Overview
    • 9.5.9.2. Financial Performance
    • 9.5.9.3. Product Benchmarking
    • 9.5.9.4. Strategic Initiatives
  • 9.5.10. Eli Lilly and Company
    • 9.5.10.1. Overview
    • 9.5.10.2. Financial Performance
    • 9.5.10.3. Product Benchmarking
    • 9.5.10.4. Strategic Initiatives
  • 9.5.11. Almirall, S.A
    • 9.5.11.1. Overview
    • 9.5.11.2. Financial Performance
    • 9.5.11.3. Product Benchmarking
    • 9.5.11.4. Strategic Initiatives
  • 9.5.12. Bausch Health Companies Inc.
    • 9.5.12.1. Overview
    • 9.5.12.2. Financial Performance
    • 9.5.12.3. Product Benchmarking
    • 9.5.12.4. Strategic Initiatives

List of Tables

• Table 1 List of secondary sources
• Table 2 List of abbreviations
• Table 3 U.S. dermatological drugs market, by therapy, 2018 - 2030 (USD Million)
• Table 4 U.S. dermatological drugs market, by type, 2018 - 2030 (USD Million)
• Table 5 U.S. dermatological drugs market, by route of adminstration, 2018 - 2030 (USD Million)
• Table 6 U.S. dermatological drugs market, by drug class, 2018 - 2030 (USD Million)
• Table 7 U.S. dermatological drugs market, by distribution channel, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 U.S. dermatological drugs market segmentation
• Fig. 2 Market research process
• Fig. 3 Data triangulation techniques
• Fig. 4 Primary research pattern
• Fig. 5 Market research approaches
• Fig. 6 Value-chain-based sizing & forecasting
• Fig. 7 Market formulation & validation
• Fig. 8 Market snapshot
• Fig. 9 Therapy and type outlook (USD Million)
• Fig. 10 Route of administration & drug class outlook (USD Million)
• Fig. 11 Distribution channel outlook (USD Million)
• Fig. 12 Competitive landscape
• Fig. 13 U.S. dermatological drugs market dynamics
• Fig. 14 U.S. dermatological drugs market: Porter's five forces analysis
• Fig. 15 U.S. dermatological drugs market: PESTLE analysis
• Fig. 16 U.S. dermatological drugs market: Therapy segment dashboard
• Fig. 17 U.S. dermatological drugs market: Therapy market share analysis, 2024 & 2030
• Fig. 18 Acne market, 2018 - 2030 (USD Million)
• Fig. 19 Psoriasis market, 2018 - 2030 (USD Million)
• Fig. 20 Rosacea market, 2018 - 2030 (USD Million)
• Fig. 21 Alopecia market, 2018 - 2030 (USD Million)
• Fig. 22 Others market, 2018 - 2030 (USD Million)
• Fig. 23 U.S. dermatological drugs market: Type segment dashboard
• Fig. 24 U.S. dermatological drugs market: Type market share analysis, 2024 & 2030
• Fig. 25 Prescription market, 2018 - 2030 (USD Million)
• Fig. 26 Over-the-Counter (OTC) market, 2018 - 2030 (USD Million)
• Fig. 27 U.S. dermatological drugs market: Route of administration segment dashboard
• Fig. 28 U.S. dermatological drugs market: Route of administration market share analysis, 2024 & 2030
• Fig. 29 Topical administration market, 2018 - 2030 (USD Million)
• Fig. 30 Oral administration market, 2018 - 2030 (USD Million)
• Fig. 31 Parenteral administration market, 2018 - 2030 (USD Million)
• Fig. 32 U.S. dermatological drugs market: Drug class segment dashboard
• Fig. 33 U.S. dermatological drugs market: Drug class market share analysis, 2024 & 2030
• Fig. 34 Corticosteroids market, 2018 - 2030 (USD Million)
• Fig. 35 Retinoids market, 2018 - 2030 (USD Million)
• Fig. 36 Antibiotics market, 2018 - 2030 (USD Million)
• Fig. 37 Antifungals market, 2018 - 2030 (USD Million)
• Fig. 38 Calcineurin inhibitors market, 2018 - 2030 (USD Million)
• Fig. 39 Others market, 2018 - 2030 (USD Million)
• Fig. 40 U.S. dermatological drugs market: Distribution channel segment dashboard
• Fig. 41 U.S. dermatological drugs market: Distribution channel market share analysis, 2024 & 2030
• Fig. 42 Hospital pharmacies market, 2018 - 2030 (USD Million)
• Fig. 43 Retail pharmacies market, 2018 - 2030 (USD Million)
• Fig. 44 Others market, 2018 - 2030 (USD Million)
• Fig. 45 Company categorization
• Fig. 46 Company market position analysis
• Fig. 47 Strategic framework